A Genetic System in Yeast for Functional Identification of Human p53 Mutations


Mutations in the p53 gene are associated with 50% of all cancers and nearly 80% of the p53 mutations are missense changes. We have developed genetic assays based in yeast that can functionally categorize expressed p53 mutant proteins. The combined assays are referred to as the FIP53 system. Because human p53 cDNA can be conveniently cloned in yeast, the FIP53 system provides a rapid and sophisticated system for the functional analysis of p53 mutants. Four categories of mutations have already been identified. The FIP53 system provides the first in vivo battery for tests that can subdivide many p53 mutations that can occur in humans. In particular, the FIP53 system may allow the identification of rare or new alleles that may function better than the wild type.

Potential Commercial Applications: Competitive Advantages:
  • The FIP53 system provides a convenient genetic system for categorizing human mutations. It can also be used to assay potential drug impacts on p53 and for design of such drugs. It can also be used to identify p53 alleles with increased transcriptional capability for various p53 target genes or mutations with different DNA sequence selectivity. Such p53 alleles may be good candidates for p53 based cancer gene therapy.
 


Inventors:

Michael Resnick (NIEHS)  ➽ more inventions...

Alberto Inga (NIEHS)  ➽ more inventions...


Intellectual Property:
U.S. Pat: 7,256,260 issued 2007-08-14
PCT Application No. PCT/US00/20538
US Application No. 10/048,502
US Application No. 11/893,037

Publications:
Inga A, Resnick MA. PMID 11423991
Resnick MA, Inga A. US Patent 7,256,260

Licensing Contact:
Uri Reichman, Ph.D., M.B.A.
Email: uri.reichman@nih.gov
Phone: 301-435-4616

OTT Reference No: E-183-1999-0
Updated: May 18, 2018